ProCE Banner Activity

CE / CME

State of the ART: Safety and Tolerability Data Discussions From Summer 2022

Video

Hear updates about ART safety and tolerability highlighting special populations such as those with cardiometabolic toxicities and aging PWH from summer 2022, including select studies from the AIDS 2022 meeting.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour, including 0.50 hour of pharmacotherapy credit 

Released: November 03, 2022

Expiration: November 02, 2023

No longer available for credit.

Share

Faculty

Jennifer Cocohoba

Jennifer Cocohoba, PharmD

Professor
Department of Clinical Pharmacy
University of California, San Francisco
Pharmacist
Womens HIV Program
University of California San Francisco Medical Center
San Francisco, California

Joseph J. Eron, Jr.

Joseph J. Eron, Jr., MD

Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology
Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Janssen Therapeutics Division of Janssen Products and ViiV Healthcare.

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with HIV infection.

Program Learning Goal

The goal of this activity is to improve learners’ competence in individualizing ART regimens for HIV by examining patient characteristics and the latest ART safety and tolerability data.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply appropriate ART modification strategies for patients experiencing adverse events or poor tolerability while receiving a virologically suppressive regimen
  • Incorporate patient characteristics into ART strategies to optimize HIV care for special populations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Jennifer Cocohoba, PharmD: researcher: Genentech, Janssen, ViiV Healthcare, Walgreens.

Joseph J. Eron, Jr., MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV; researcher: Gilead Sciences, ViiV.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 03, 2022, through November 02, 2023:

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacology credit.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-273-H02-P

Type of Activity
: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.